| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Embolization, Therapeutic | 20 | 2026 | 223 | 4.630 |
Why?
|
| Thrombectomy | 26 | 2026 | 112 | 4.480 |
Why?
|
| Hematoma, Subdural, Chronic | 9 | 2025 | 13 | 3.370 |
Why?
|
| Meningeal Arteries | 11 | 2025 | 14 | 2.410 |
Why?
|
| Stroke | 22 | 2026 | 1082 | 2.130 |
Why?
|
| Bone Screws | 8 | 2015 | 53 | 2.080 |
Why?
|
| Endovascular Procedures | 17 | 2026 | 785 | 1.840 |
Why?
|
| Atlanto-Axial Joint | 8 | 2015 | 22 | 1.770 |
Why?
|
| Intracranial Aneurysm | 9 | 2026 | 91 | 1.640 |
Why?
|
| Stents | 15 | 2026 | 874 | 1.610 |
Why?
|
| Tinnitus | 2 | 2023 | 23 | 1.560 |
Why?
|
| Treatment Outcome | 60 | 2026 | 13027 | 1.270 |
Why?
|
| Neurosurgical Procedures | 6 | 2020 | 317 | 1.100 |
Why?
|
| Cranial Sinuses | 2 | 2023 | 13 | 0.980 |
Why?
|
| Propensity Score | 7 | 2025 | 255 | 0.970 |
Why?
|
| Cerebral Hemorrhage | 6 | 2025 | 158 | 0.970 |
Why?
|
| Aged, 80 and over | 33 | 2026 | 7138 | 0.890 |
Why?
|
| Magnesium Sulfate | 1 | 2024 | 51 | 0.880 |
Why?
|
| Cervical Vertebrae | 2 | 2015 | 117 | 0.840 |
Why?
|
| Aged | 50 | 2026 | 21482 | 0.830 |
Why?
|
| Drainage | 2 | 2016 | 262 | 0.800 |
Why?
|
| Neuroprotective Agents | 1 | 2024 | 161 | 0.800 |
Why?
|
| Retrospective Studies | 48 | 2026 | 17395 | 0.790 |
Why?
|
| Cerebral Revascularization | 3 | 2023 | 22 | 0.790 |
Why?
|
| Constriction, Pathologic | 7 | 2023 | 235 | 0.780 |
Why?
|
| Middle Aged | 53 | 2026 | 29021 | 0.760 |
Why?
|
| Hematoma, Subdural | 2 | 2023 | 25 | 0.690 |
Why?
|
| Spinal Fusion | 7 | 2018 | 114 | 0.670 |
Why?
|
| Brain Ischemia | 5 | 2023 | 278 | 0.660 |
Why?
|
| Humans | 93 | 2026 | 132247 | 0.630 |
Why?
|
| Craniotomy | 3 | 2016 | 108 | 0.610 |
Why?
|
| Cervical Atlas | 2 | 2016 | 7 | 0.600 |
Why?
|
| Joint Instability | 3 | 2013 | 59 | 0.580 |
Why?
|
| Vertebral Artery | 3 | 2014 | 22 | 0.570 |
Why?
|
| Angioplasty | 4 | 2024 | 76 | 0.550 |
Why?
|
| Male | 58 | 2026 | 65012 | 0.540 |
Why?
|
| Female | 59 | 2026 | 70785 | 0.520 |
Why?
|
| Arthrodesis | 2 | 2015 | 14 | 0.500 |
Why?
|
| Neurosurgery | 2 | 2014 | 82 | 0.490 |
Why?
|
| Tranexamic Acid | 1 | 2016 | 33 | 0.480 |
Why?
|
| Antifibrinolytic Agents | 1 | 2016 | 49 | 0.470 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2025 | 2166 | 0.460 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2026 | 36 | 0.460 |
Why?
|
| Anticoagulants | 3 | 2023 | 609 | 0.440 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 74 | 0.430 |
Why?
|
| Registries | 10 | 2026 | 1591 | 0.430 |
Why?
|
| Angioplasty, Balloon | 2 | 2025 | 159 | 0.420 |
Why?
|
| Spinal Injuries | 1 | 2013 | 33 | 0.410 |
Why?
|
| Aneurysm, Ruptured | 2 | 2015 | 35 | 0.410 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 137 | 0.400 |
Why?
|
| Arachnoid | 2 | 2023 | 9 | 0.400 |
Why?
|
| Betacoronavirus | 3 | 2020 | 299 | 0.380 |
Why?
|
| Spinal Cord | 2 | 2021 | 276 | 0.380 |
Why?
|
| Prostheses and Implants | 1 | 2014 | 153 | 0.380 |
Why?
|
| Carotid Stenosis | 2 | 2025 | 123 | 0.370 |
Why?
|
| Heparin | 1 | 2013 | 212 | 0.370 |
Why?
|
| Fibrinolytic Agents | 2 | 2025 | 207 | 0.370 |
Why?
|
| Arteries | 1 | 2012 | 222 | 0.350 |
Why?
|
| Thrombolytic Therapy | 2 | 2025 | 216 | 0.350 |
Why?
|
| Aneurysm, False | 1 | 2012 | 93 | 0.350 |
Why?
|
| Vascular Diseases | 1 | 2012 | 150 | 0.340 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 379 | 0.330 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 185 | 0.330 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 390 | 0.330 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 299 | 0.330 |
Why?
|
| Surgeons | 1 | 2015 | 286 | 0.330 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 2023 | 33 | 0.320 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 663 | 0.320 |
Why?
|
| Middle Cerebral Artery | 3 | 2021 | 115 | 0.320 |
Why?
|
| Cerebral Angiography | 3 | 2026 | 107 | 0.300 |
Why?
|
| Adult | 20 | 2026 | 31614 | 0.300 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2022 | 70 | 0.280 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 697 | 0.270 |
Why?
|
| Radial Artery | 2 | 2025 | 33 | 0.270 |
Why?
|
| Angiography | 2 | 2020 | 208 | 0.260 |
Why?
|
| Anesthesia, General | 2 | 2024 | 124 | 0.250 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2020 | 515 | 0.240 |
Why?
|
| Decompressive Craniectomy | 1 | 2025 | 15 | 0.230 |
Why?
|
| Neuroimaging | 2 | 2025 | 375 | 0.220 |
Why?
|
| Recovery of Function | 2 | 2024 | 463 | 0.220 |
Why?
|
| Femoral Artery | 1 | 2025 | 168 | 0.220 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2025 | 121 | 0.220 |
Why?
|
| Reperfusion | 2 | 2020 | 26 | 0.210 |
Why?
|
| Radiosurgery | 2 | 2016 | 147 | 0.210 |
Why?
|
| Carotid Artery, Internal | 3 | 2024 | 58 | 0.210 |
Why?
|
| Skull | 3 | 2023 | 143 | 0.200 |
Why?
|
| Blood Coagulation Disorders | 1 | 2024 | 109 | 0.200 |
Why?
|
| Moyamoya Disease | 1 | 2023 | 42 | 0.190 |
Why?
|
| Vasospasm, Intracranial | 1 | 2022 | 19 | 0.190 |
Why?
|
| Balloon Embolectomy | 2 | 2018 | 2 | 0.190 |
Why?
|
| Fetal Stem Cells | 2 | 2012 | 5 | 0.190 |
Why?
|
| Drug-Eluting Stents | 1 | 2023 | 69 | 0.190 |
Why?
|
| Combined Modality Therapy | 3 | 2025 | 1294 | 0.180 |
Why?
|
| Urinary Retention | 1 | 2021 | 19 | 0.180 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2021 | 8 | 0.180 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2012 | 84 | 0.180 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2021 | 17 | 0.180 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 119 | 0.180 |
Why?
|
| Patient Selection | 1 | 2025 | 731 | 0.180 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 35 | 0.180 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 64 | 0.170 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2012 | 108 | 0.170 |
Why?
|
| Temporal Arteries | 1 | 2021 | 39 | 0.170 |
Why?
|
| New York City | 4 | 2021 | 65 | 0.170 |
Why?
|
| Brain Infarction | 1 | 2020 | 30 | 0.170 |
Why?
|
| Pandemics | 4 | 2021 | 1186 | 0.170 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2020 | 20 | 0.170 |
Why?
|
| Pons | 1 | 2020 | 35 | 0.170 |
Why?
|
| Time-to-Treatment | 4 | 2024 | 211 | 0.170 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 31 | 0.160 |
Why?
|
| Comprehensive Health Care | 1 | 2020 | 17 | 0.160 |
Why?
|
| Skull Base | 2 | 2020 | 51 | 0.160 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 39 | 0.160 |
Why?
|
| Empirical Research | 1 | 2019 | 9 | 0.160 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 35 | 0.160 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 48 | 0.160 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 1410 | 0.150 |
Why?
|
| Arteriovenous Fistula | 1 | 2020 | 55 | 0.150 |
Why?
|
| Catheters | 3 | 2024 | 89 | 0.150 |
Why?
|
| Neoplasms | 1 | 2014 | 2961 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 119 | 0.150 |
Why?
|
| Glioblastoma | 1 | 2022 | 374 | 0.150 |
Why?
|
| Biomechanical Phenomena | 2 | 2018 | 229 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 143 | 0.140 |
Why?
|
| Hyperglycemia | 1 | 2020 | 235 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2025 | 3139 | 0.140 |
Why?
|
| Spinal Diseases | 1 | 2018 | 46 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 236 | 0.140 |
Why?
|
| Glioma | 1 | 2022 | 535 | 0.140 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 113 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2014 | 277 | 0.130 |
Why?
|
| Time Factors | 5 | 2024 | 6451 | 0.130 |
Why?
|
| Neuroendoscopy | 1 | 2016 | 30 | 0.130 |
Why?
|
| Epidermal Cyst | 1 | 2016 | 18 | 0.130 |
Why?
|
| Nervous System Neoplasms | 1 | 2016 | 9 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2020 | 1121 | 0.120 |
Why?
|
| Dermoid Cyst | 1 | 2016 | 34 | 0.120 |
Why?
|
| Finite Element Analysis | 1 | 2016 | 35 | 0.120 |
Why?
|
| Epilepsy | 2 | 2016 | 891 | 0.120 |
Why?
|
| Recurrence | 3 | 2026 | 1453 | 0.120 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2015 | 12 | 0.120 |
Why?
|
| Printing, Three-Dimensional | 1 | 2016 | 68 | 0.120 |
Why?
|
| Models, Anatomic | 1 | 2016 | 104 | 0.110 |
Why?
|
| Health Personnel | 1 | 2020 | 545 | 0.110 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 38 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1161 | 0.110 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 124 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2022 | 3414 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2015 | 188 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 700 | 0.110 |
Why?
|
| Young Adult | 5 | 2016 | 9966 | 0.110 |
Why?
|
| Computer-Assisted Instruction | 1 | 2014 | 53 | 0.100 |
Why?
|
| Patients | 1 | 2015 | 129 | 0.100 |
Why?
|
| Thrombosis | 1 | 2018 | 528 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2025 | 364 | 0.100 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 63 | 0.100 |
Why?
|
| Cadaver | 1 | 2013 | 119 | 0.100 |
Why?
|
| Hydrocephalus | 1 | 2016 | 277 | 0.100 |
Why?
|
| Physician's Role | 1 | 2015 | 168 | 0.100 |
Why?
|
| Data Collection | 1 | 2015 | 391 | 0.100 |
Why?
|
| Osteoarthritis, Spine | 1 | 2012 | 2 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 327 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 437 | 0.100 |
Why?
|
| Alberta | 2 | 2023 | 66 | 0.090 |
Why?
|
| Braces | 1 | 2012 | 14 | 0.090 |
Why?
|
| Arachnoid Cysts | 1 | 2012 | 7 | 0.090 |
Why?
|
| Thoracic Vertebrae | 1 | 2012 | 68 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 818 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2013 | 232 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 380 | 0.090 |
Why?
|
| Pain | 1 | 2015 | 462 | 0.090 |
Why?
|
| Risk Factors | 5 | 2025 | 10945 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2016 | 1444 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 893 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2014 | 368 | 0.090 |
Why?
|
| Hypothalamic Diseases | 1 | 2012 | 38 | 0.090 |
Why?
|
| Hospitalization | 2 | 2020 | 1902 | 0.090 |
Why?
|
| Hamartoma | 1 | 2012 | 52 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 761 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2026 | 5176 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 482 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 394 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 249 | 0.080 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2011 | 58 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 982 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 3093 | 0.080 |
Why?
|
| Animals | 5 | 2024 | 34850 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 341 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 725 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 564 | 0.070 |
Why?
|
| Adolescent | 4 | 2016 | 20557 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2025 | 6568 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 890 | 0.070 |
Why?
|
| United States | 3 | 2023 | 11669 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2026 | 5410 | 0.060 |
Why?
|
| Myocardium | 1 | 2011 | 907 | 0.060 |
Why?
|
| Prevalence | 1 | 2013 | 2664 | 0.060 |
Why?
|
| Child | 6 | 2016 | 25783 | 0.060 |
Why?
|
| Mechanical Thrombolysis | 1 | 2025 | 10 | 0.060 |
Why?
|
| Infarction, Anterior Cerebral Artery | 1 | 2024 | 2 | 0.060 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2024 | 7 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2025 | 162 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2025 | 154 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1965 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2025 | 198 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 1062 | 0.050 |
Why?
|
| Incidence | 2 | 2023 | 3376 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2014 | 1258 | 0.050 |
Why?
|
| Polymethyl Methacrylate | 1 | 2023 | 15 | 0.050 |
Why?
|
| Cerebral Infarction | 1 | 2023 | 45 | 0.050 |
Why?
|
| Anterior Cerebral Artery | 1 | 2022 | 8 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 50 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 71 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 81 | 0.050 |
Why?
|
| Retreatment | 1 | 2022 | 93 | 0.050 |
Why?
|
| Paraparesis | 1 | 2021 | 8 | 0.050 |
Why?
|
| Walruses | 1 | 2021 | 1 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 289 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 4690 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 66 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 208 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 3404 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2012 | 395 | 0.040 |
Why?
|
| Constipation | 1 | 2021 | 128 | 0.040 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2020 | 21 | 0.040 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2020 | 10 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 29 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 39 | 0.040 |
Why?
|
| Causality | 1 | 2020 | 94 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2020 | 41 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 33 | 0.040 |
Why?
|
| Troponin | 1 | 2020 | 79 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2020 | 79 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2020 | 75 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 134 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 56 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 3853 | 0.040 |
Why?
|
| Monitoring, Intraoperative | 1 | 2020 | 132 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 187 | 0.040 |
Why?
|
| Aphasia | 1 | 2018 | 14 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 821 | 0.040 |
Why?
|
| Age Factors | 1 | 2025 | 2923 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 288 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2023 | 988 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 81 | 0.030 |
Why?
|
| Brain | 2 | 2022 | 3194 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 576 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2233 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2196 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1610 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 130 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2015 | 86 | 0.030 |
Why?
|
| Cerebral Arteries | 1 | 2015 | 83 | 0.030 |
Why?
|
| Prognosis | 1 | 2023 | 5016 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1966 | 0.020 |
Why?
|
| Zygapophyseal Joint | 1 | 2012 | 4 | 0.020 |
Why?
|
| Neck Pain | 1 | 2012 | 19 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2011 | 10 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 424 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 229 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 308 | 0.020 |
Why?
|
| Headache | 1 | 2012 | 110 | 0.020 |
Why?
|
| Infant | 2 | 2016 | 13049 | 0.020 |
Why?
|
| Calcinosis | 1 | 2012 | 191 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 862 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2016 | 14736 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 238 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 802 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2012 | 217 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 469 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 852 | 0.020 |
Why?
|
| Pregnancy | 2 | 2012 | 7557 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 486 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 569 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1288 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2011 | 390 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1500 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2011 | 652 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2451 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2011 | 908 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 3046 | 0.010 |
Why?
|
| Mice | 2 | 2012 | 18507 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8548 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 4758 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2011 | 2491 | 0.010 |
Why?
|